Background: Emerging evidence suggests the presence of neuroanatomical abnormalities in subjects with autism spectrum disorder (ASD). Identifying anatomical correlates could thus prove useful for the automated diagnosis of ASD. Radiomic analyses based on MRI texture features have shown a great potential for characterizing differences occurring from tissue heterogeneity, and for identifying abnormalities related to these differences. However, only a limited number of studies have investigated the link between image texture and ASD. This paper proposes the study of texture features based on grey level co-occurrence matrix (GLCM) as a means for characterizing differences between ASD and development control (DC) subjects. Our study uses 64 T1-weighted MRI scans acquired from two groups of subjects: 28 typical age range subjects 4-15 years old (14 ASD and 14 DC, age-matched), and 36 non-typical age range subjects 10-24 years old (20 ASD and 16 DC). GLCM matrices are computed from manually labeled hippocampus and amygdala regions, and then encoded as texture features by applying 11 standard Haralick quantifier functions. Significance tests are performed to identify texture differences between ASD and DC subjects. An analysis using SVM and random forest classifiers is then carried out to find the most discriminative features, and use these features for classifying ASD from DC subjects.
Results:Preliminary results show that all 11 features derived from the hippocampus (typical and non-typical age) and 4 features extracted from the amygdala (non-typical age) have significantly different distributions in ASD subjects compared to DC subjects, with a significance of p < 0.05 following Holm-Bonferroni correction. Features derived from hippocampal regions also demonstrate high discriminative power for differentiating between ASD and DC subjects, with classifier accuracy of 67.85%, sensitivity of 62.50%, specificity of 71.42%, and the area under the ROC curve (AUC) of 76.80% for age-matched subjects with typical age range.
Conclusions:Results demonstrate the potential of hippocampal texture features as a biomarker for the diagnosis and characterization of ASD.
PurposeThis paper proposes to characterize the continuum of colorectal cancer (CRC) using multiple texture features extracted from multispectral optical microscopy images. Three types of pathological tissues (PT) are considered: benign hyperplasia, intraepithelial neoplasia and carcinoma.Materials and MethodsIn the proposed approach, the region of interest containing PT is first extracted from multispectral images using active contour segmentation. This region is then encoded using texture features based on the Laplacian-of-Gaussian (LoG) filter, discrete wavelets (DW) and gray level co-occurrence matrices (GLCM). To assess the significance of textural differences between PT types, a statistical analysis based on the Kruskal-Wallis test is performed. The usefulness of texture features is then evaluated quantitatively in terms of their ability to predict PT types using various classifier models.ResultsPreliminary results show significant texture differences between PT types, for all texture features (p-value < 0.01). Individually, GLCM texture features outperform LoG and DW features in terms of PT type prediction. However, a higher performance can be achieved by combining all texture features, resulting in a mean classification accuracy of 98.92%, sensitivity of 98.12%, and specificity of 99.67%.ConclusionsThese results demonstrate the efficiency and effectiveness of combining multiple texture features for characterizing the continuum of CRC and discriminating between pathological tissues in multispectral images.
scite is a Brooklyn-based startup that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.